The emerging role of serotonin in liver regeneration

Autor: George K Papadimas, Konstantinos N Tzirogiannis, Michael G Mykoniatis, Agni D Grypioti, Georgia A Manta, Georgios I Panoutsopoulos

Publikováno v: Swiss Medical Weekly, Vol 142, Iss 1516 (2012)

Serotonin has a multifunctional role in many different organs serving either as a neurotransmitter in the central nervous system or a paracrine factor in the gastrointestinal tract. Over 90% of serotonin is synthesised in the enterochromaffin cells o

Externí odkaz: https://doaj.org/article/865ddff1607747d6af0140af237da26e

Stiff-Leg Syndrome Associated with Autoimmune Retinopathy and Its Treatment with IVIg—A Case Report and Review of the Literature

Autor: Vassilis E. Papadopoulos, George K. Papadimas, Sofia Androudi, Maria Anagnostouli, Maria-Eleftheria Evangelopoulos

Publikováno v: Brain Sciences, Vol 13, Iss 10, p 1361 (2023)

Antibodies to glutamic acid decarboxylase (GAD) have been predominantly associated with stiff-person syndrome (SPS), which is often accompanied by organ-specific autoimmune diseases, such as late-onset type 1 diabetes. Autoimmune retinal pathology in

Externí odkaz: https://doaj.org/article/d50a3e1c54ec4f0a938759865cb4f343

Neuropsychological Assessment Should Always be Considered in Myotonic Dystrophy Type 2

Autor: Varvara Pantoleon, Thomas Theodosiou, George K. Papadimas, Constantinos Papadopoulos, Peter Bede, Panagiotis Kourtesis, Foteini Christidi, Efstratios Karavasilis, Ioannis Zalonis, Sofia Xirou, Evangelia Kararizou

Publikováno v: Cognitive and Behavioral Neurology. 34:1-10

Myotonic dystrophies (DMs) are hereditary, multisystem, slowly progressive myopathies. One of the systems they affect is the CNS. In contrast to the well-established cognitive profile of myotonic dystrophy type 1 (DM1), only a few studies have invest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c30bbe8c185e87c2030efc8a97c0e21f
https://doi.org/10.1097/wnn.0000000000000263

miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1

Autor: Konstantinos Kapnisis, Leonidas A. Phylactou, George M. Spyrou, Geneviève Gourdon, George K. Papadimas, Chris Turner, Marianna Prokopi, Andreas S. Anayiotos, Anna Lusakowska, Hanns Lochmüller, Nikoletta Nikolenko, Demetris Koutalianos, Constantinos Papadopoulos, Chrystalla Mytidou, Anastasis Oulas, Tassos C. Kyriakides, Katarzyna Janiszewska, Grainne S. Gorman, Eleni Zamba Papanicolaou, Andrea C. Kakouri, Marios Tomazou, Andrie Koutsoulidou, Evangelia Kararizou

Publikováno v: Molecular Therapy-Methods and Clinical Development
Molecular Therapy-Methods and Clinical Development, Nature Publishing Group, 2021, 23, pp.169-183. ⟨10.1016/j.omtm.2021.09.007⟩
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss, Pp 169-183 (2021)

Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy, primarily characterized by muscle wasting and weakness. Many biomarkers already exist in the rapidly developing biomarker research field that aim to improve patients�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8b23e128f936dd313386b4a8aca3c9
https://hal.sorbonne-universite.fr/hal-03408757/document

Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience

Autor: Gerasimos Terzis, Sophia Xirou, George K. Papadimas, Helen Michelakakis, Christoforos Anagnostopoulos, Evangelia Kararizou, Constantinos Papadopoulos, Irene Mavridou

Publikováno v: Neuromuscular disorders : NMD. 31(2)

Late onset Pompe disease (LOPD) is a slowly progressive metabolic myopathy with variable clinical severity. The advent of enzyme replacement therapy (ERT) has modified the natural course of the disease, though the treatment effect on adult patients i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882e3e5b0a1b3e5c60db1d6f6081dc94
https://pubmed.ncbi.nlm.nih.gov/33451932